The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare syste...

Ausführliche Beschreibung

Gespeichert in:

Bibliografische Detailangaben
Hauptverfasser:	Doreen A. Ezeife, Eldon Spackman, Rosalyn A. Juergens, Janessa J. Laskin, Jason S. Agulnik, Desiree Hao, Scott A. Laurie, Jennifer H. Law, Lisa W. Le, Lesli A. Kiedrowski, Barbara Melosky, Frances A. Shepherd, Victor Cohen, Paul Wheatley-Price, Rachel Vandermeer, Janice J. Li, Roxanne Fernandes, Aria Shokoohi, Richard B. Lanman, Natasha B. Leighl
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SAGE Publishing 2022-07-01
Schriftenreihe:	Therapeutic Advances in Medical Oncology
Online-Zugang:	https://doi.org/10.1177/17588359221112696
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

Ähnliche Einträge